Literature DB >> 16430961

Recombinant glutathione-S-transferase a major allergen from Alternaria alternata for clinical use in allergy patients.

Jay Shankar1, Bhanu P Singh, Shailendra N Gaur, Naveen Arora.   

Abstract

Recombinant proteins are used for vaccines, therapy and diagnosis of many diseases. Biological activity of these may differ from native counterpart and needs investigation. The present study aimed to compare recombinant (r) and native (n) glutathione-S-transferase (GST) from Alternaria alternata. Glutathione-S-transferase sequence showed an ORF of 696bp encoding 26-kDa protein with N-terminus conserved domain. Secondary structure of both forms was comparable with melting temperature of 57 and 59 degrees C, respectively. rGST and nGST showed similar enzymatic activity, allergenicity and potency by ELISA inhibition. Histamine release was comparable in 14/17 patients for both the GSTs. rGST and nGST induced proliferation in PBMC at different concentration. Cell supernatant revealed higher IL-4 and IL-5 levels with low levels of IFN-gamma. In summary, recombinant and native GST demonstrated similar physio-chemical, biological and immunological properties and induced comparable cell mediated and humoral response to be used for diagnosis and specific immunotherapy for the fungal allergy cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430961     DOI: 10.1016/j.molimm.2005.12.006

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  19 in total

1.  Engineered Alt a 13 fragment of Alternaria alternata abrogated IgE binding without affecting T-cell stimulation.

Authors:  Jay Shankar; Bhanu P Singh; Shailendra N Gaur; Naveen Arora
Journal:  J Clin Immunol       Date:  2008-08-06       Impact factor: 8.317

2.  Characterization of recombinant per a 10 from Periplaneta americana.

Authors:  Dhanapal Govindaraj; Shailendra Nath Gaur; Naveen Arora
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

3.  Identification and biochemical characterisation of Asp t 36, a new fungal allergen from Aspergillus terreus.

Authors:  Bijoya Karmakar; Bodhisattwa Saha; Kuladip Jana; Swati Gupta Bhattacharya
Journal:  J Biol Chem       Date:  2020-10-20       Impact factor: 5.157

4.  Cloning, recombinant expression and activity studies of a major allergen "enolase" from the fungus Curvularia lunata.

Authors:  Vidhu Sharma; Ratna Gupta; Anupam Jhingran; Bhanu Pratap Singh; Susheela Sridhara; Shailendra Nath Gaur; Naveen Arora
Journal:  J Clin Immunol       Date:  2006-06-16       Impact factor: 8.317

Review 5.  Human Helminths and Allergic Disease: The Hygiene Hypothesis and Beyond.

Authors:  Helton C Santiago; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

6.  Effect of proteolytic activity of Epicoccum purpurascens major allergen, Epi p 1 in allergic inflammation.

Authors:  N Kukreja; S Sridhara; B P Singh; N Arora
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

7.  Immunoglobulin E (IgE)-mediated cross-reactivity between mesquite pollen proteins and lima bean, an edible legume.

Authors:  A Dhyani; N Arora; V K Jain; S Sridhara; B P Singh
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

Review 8.  Alternaria alternata and its allergens: a comprehensive review.

Authors:  Irena Kustrzeba-Wójcicka; Emilia Siwak; Grzegorz Terlecki; Anna Wolańczyk-Mędrala; Wojciech Mędrala
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 9.  Current immunological approaches for management of allergic rhinitis and bronchial asthma.

Authors:  Deepsikha Srivastava; Naveen Arora; Bhanu Pratap Singh
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

10.  Identification and biochemical characterization of Asp t 36, a new fungal allergen from Aspergillus terreus.

Authors:  Bijoya Karmakar; Bodhisattwa Saha; Kuladip Jana; Swati Gupta Bhattacharya
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.